Sionna Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
SION$3.70+3.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(54,828) | $(45,840) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 8,240 | 2,644 |
| Non-cash operating lease expense | 1,471 | 1,472 |
| Amortization of discount on marketable securities | (2,699) | (2,211) |
| Non-cash expense related to IPR&D acquisition | — | 8,639 |
| Depreciation expense | 495 | 501 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (543) | (2,177) |
| Accounts payable | 295 | (615) |
| Accrued expenses and other current liabilities | (517) | (2,094) |
| Operating lease liabilities | (1,585) | (1,369) |
| Other assets | — | 44 |
| Net cash used in operating activities | (49,671) | (41,006) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (173) | — |
| Purchases of marketable securities | (282,147) | (175,641) |
| Maturities of marketable securities | 140,983 | 33,500 |
| Net cash used in investing activities | (141,337) | (142,141) |
| Cash flows from financing activities: | ||
| Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period | 202,071 | — |
| Proceeds from issuance of Series C convertible preferred stock, net of issuance costs | — | 181,328 |
| Payment of deferred offering costs | — | (1,069) |
| Exercise of common stock options | 1,980 | 116 |
| Net cash provided by financing activities | 204,051 | 180,375 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 13,043 | (2,772) |
| Cash, cash equivalents and restricted cash at beginning of period | 38,750 | 39,483 |
| Cash, cash equivalents and restricted cash at end of period | $51,793 | $36,711 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Conversion of convertible preferred stock into common stock upon closing of initial public offering | $330,368 | $— |
| Offering costs transferred to additional paid in capital | 4,265 | — |
| Deferred offering costs in accrued expenses | — | 851 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $50,831 | $35,749 |
| Restricted cash | 962 | 962 |
| Total cash, cash equivalents, and restricted cash | $51,793 | $36,711 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.